nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—UGT1A1—Irinotecan—breast cancer	0.124	1	CbGbCtD
Dolutegravir—POU2F2—mammary gland—breast cancer	0.035	0.294	CbGeAlD
Dolutegravir—POU2F2—nipple—breast cancer	0.029	0.243	CbGeAlD
Dolutegravir—POU2F2—adipose tissue—breast cancer	0.0158	0.132	CbGeAlD
Dolutegravir—POU2F2—adrenal gland—breast cancer	0.0141	0.119	CbGeAlD
Dolutegravir—POU2F2—female gonad—breast cancer	0.0132	0.111	CbGeAlD
Dolutegravir—POU2F2—lymph node—breast cancer	0.00848	0.0711	CbGeAlD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—BRCA2—breast cancer	0.0042	0.0126	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—VDR—breast cancer	0.00406	0.0122	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—THRB—breast cancer	0.00404	0.0121	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—HES1—breast cancer	0.00397	0.0119	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—NRG1—breast cancer	0.00387	0.0116	CbGpPWpGaD
Dolutegravir—UGT1A1—endocrine gland—breast cancer	0.0037	0.031	CbGeAlD
Dolutegravir—UGT1A1—Irinotecan Pathway—ABCC1—breast cancer	0.00358	0.0107	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—PPARGC1B—breast cancer	0.00349	0.0105	CbGpPWpGaD
Dolutegravir—UGT1A1—Codeine and Morphine Metabolism—CYP2D6—breast cancer	0.00339	0.0102	CbGpPWpGaD
Dolutegravir—UGT1A1—Heme degradation—HMOX1—breast cancer	0.00318	0.00953	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—ATM—breast cancer	0.00313	0.00938	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—NOTCH1—breast cancer	0.003	0.00899	CbGpPWpGaD
Dolutegravir—UGT1A1—Codeine and Morphine Metabolism—CYP3A4—breast cancer	0.00299	0.00897	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—FOXM1—breast cancer	0.00293	0.0088	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—WNT1—breast cancer	0.00283	0.00848	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—BMP4—breast cancer	0.00275	0.00825	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—ALDOA—breast cancer	0.00264	0.00792	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—SULT1A1—breast cancer	0.00258	0.00773	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—GSTA1—breast cancer	0.00252	0.00755	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CPT1A—breast cancer	0.0025	0.00748	CbGpPWpGaD
Dolutegravir—UGT1A1—Irinotecan Pathway—ABCG2—breast cancer	0.00248	0.00744	CbGpPWpGaD
Dolutegravir—UGT1A1—Codeine and Morphine Metabolism—ABCB1—breast cancer	0.00242	0.00726	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—ALDH3A1—breast cancer	0.00241	0.00721	CbGpPWpGaD
Dolutegravir—POU2F2—Validated transcriptional targets of deltaNp63 isoforms—MDM2—breast cancer	0.00231	0.00692	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—NFKBIA—breast cancer	0.00228	0.00683	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—GATA3—breast cancer	0.00218	0.00654	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—FOS—breast cancer	0.0021	0.00631	CbGpPWpGaD
Dolutegravir—UGT1A1—Irinotecan Pathway—BCHE—breast cancer	0.00206	0.00616	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—ESR2—breast cancer	0.00196	0.00587	CbGpPWpGaD
Dolutegravir—UGT1A1—Irinotecan Pathway—CYP3A4—breast cancer	0.00191	0.00573	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—EGR1—breast cancer	0.00183	0.00549	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—RAF1—breast cancer	0.00173	0.00519	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—AR—breast cancer	0.00173	0.00519	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—RELA—breast cancer	0.00172	0.00517	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—SMAD4—breast cancer	0.00172	0.00515	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SERPINB2—breast cancer	0.00167	0.005	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—GSTA2—breast cancer	0.00165	0.00494	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—SULT1A1—breast cancer	0.00163	0.00488	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—NQO1—breast cancer	0.0016	0.00481	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP3A4—breast cancer	0.00156	0.00469	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP1B1—breast cancer	0.00154	0.00461	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—FGFR2—breast cancer	0.00153	0.00459	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HES1—breast cancer	0.00152	0.00456	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—JUN—breast cancer	0.00151	0.00453	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PTEN—breast cancer	0.00146	0.00438	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK8—breast cancer	0.00143	0.00429	CbGpPWpGaD
Dolutegravir—UGT1A1—Porphyrin metabolism—HMOX1—breast cancer	0.00138	0.00414	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—COMT—breast cancer	0.00134	0.00403	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—HIF1A—breast cancer	0.00127	0.00382	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—MAPK3—breast cancer	0.00125	0.00374	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—GSTA2—breast cancer	0.00123	0.00369	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—GSTM1—breast cancer	0.00123	0.00369	CbGpPWpGaD
Dolutegravir—UGT1A1—Estrogen metabolism—CYP1A1—breast cancer	0.00117	0.00349	CbGpPWpGaD
Dolutegravir—UGT1A1—Irinotecan Pathway—APC—breast cancer	0.00112	0.00335	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—NCOA2—breast cancer	0.0011	0.00329	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—AHR—breast cancer	0.00107	0.00322	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—PIK3CA—breast cancer	0.00103	0.00309	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC2A10—breast cancer	0.00103	0.00308	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—CYP3A4—breast cancer	0.000987	0.00296	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—ALDH3A1—breast cancer	0.000955	0.00286	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—HRAS—breast cancer	0.000954	0.00286	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—HSP90AA1—breast cancer	0.000952	0.00285	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—NCOA1—breast cancer	0.000926	0.00278	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC39A7—breast cancer	0.000851	0.00255	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—AKT1—breast cancer	0.000842	0.00253	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—CTNNB1—breast cancer	0.000841	0.00252	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CXCL8—breast cancer	0.000827	0.00248	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA3—breast cancer	0.000822	0.00247	CbGpPWpGaD
Dolutegravir—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—breast cancer	0.000799	0.0024	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL1B—breast cancer	0.000793	0.00238	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CASP3—breast cancer	0.000791	0.00237	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CHST9—breast cancer	0.000777	0.00233	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—JUN—breast cancer	0.000768	0.0023	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—CTNNB1—breast cancer	0.000763	0.00229	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NQO1—breast cancer	0.000757	0.00227	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA4—breast cancer	0.000752	0.00226	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC2A5—breast cancer	0.000749	0.00225	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA2—breast cancer	0.000733	0.0022	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1B1—breast cancer	0.000726	0.00218	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—SULT1A1—breast cancer	0.000724	0.00217	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HSP90AA1—breast cancer	0.000712	0.00213	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTA1—breast cancer	0.000707	0.00212	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—NAT2—breast cancer	0.000699	0.0021	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NCOA1—breast cancer	0.000692	0.00208	CbGpPWpGaD
Dolutegravir—POU2F2—Ectoderm Differentiation—MYC—breast cancer	0.000681	0.00204	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—VEGFA—breast cancer	0.000671	0.00201	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC39A6—breast cancer	0.000645	0.00193	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HES1—breast cancer	0.000584	0.00175	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—TNF—breast cancer	0.000575	0.00173	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—MTR—breast cancer	0.00057	0.00171	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—BAX—breast cancer	0.000565	0.0017	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—HPGDS—breast cancer	0.000559	0.00168	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1A1—breast cancer	0.00055	0.00165	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA3—breast cancer	0.000548	0.00164	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTT1—breast cancer	0.000542	0.00163	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—ALDH1A1—breast cancer	0.00054	0.00162	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA4—breast cancer	0.000502	0.0015	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA2—breast cancer	0.000489	0.00147	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GPX2—breast cancer	0.000489	0.00147	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTA3—breast cancer	0.000481	0.00144	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTA3—breast cancer	0.000474	0.00142	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTA1—breast cancer	0.000472	0.00141	CbGpPWpGaD
Dolutegravir—POU2F2—SIDS Susceptibility Pathways—IL6—breast cancer	0.000464	0.00139	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTA4—breast cancer	0.00044	0.00132	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTA4—breast cancer	0.000434	0.0013	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTA2—breast cancer	0.000429	0.00129	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—SULT1A1—breast cancer	0.000424	0.00127	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GPX2—breast cancer	0.000423	0.00127	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—SULT1A1—breast cancer	0.000418	0.00125	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—GPX4—breast cancer	0.000418	0.00125	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—GSTA1—breast cancer	0.000414	0.00124	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—NAT2—breast cancer	0.000409	0.00123	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—NAT2—breast cancer	0.000403	0.00121	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC2A2—breast cancer	0.000388	0.00116	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—COMT—breast cancer	0.000378	0.00113	CbGpPWpGaD
Dolutegravir—UGT1A1—Phase II conjugation—GSTP1—breast cancer	0.000376	0.00113	CbGpPWpGaD
Dolutegravir—Diarrhoea—Melphalan—breast cancer	0.000376	0.000888	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Thiotepa—breast cancer	0.000375	0.000885	CcSEcCtD
Dolutegravir—Skin disorder—Gemcitabine—breast cancer	0.000374	0.000885	CcSEcCtD
Dolutegravir—Nausea—Chlorambucil—breast cancer	0.000374	0.000884	CcSEcCtD
Dolutegravir—Hepatitis—Capecitabine—breast cancer	0.000373	0.000881	CcSEcCtD
Dolutegravir—Nervous system disorder—Fluorouracil—breast cancer	0.000372	0.000878	CcSEcCtD
Dolutegravir—Dizziness—Tamoxifen—breast cancer	0.000371	0.000876	CcSEcCtD
Dolutegravir—Urinary tract disorder—Capecitabine—breast cancer	0.000368	0.00087	CcSEcCtD
Dolutegravir—Vomiting—Vinblastine—breast cancer	0.000367	0.000867	CcSEcCtD
Dolutegravir—Diarrhoea—Goserelin—breast cancer	0.000366	0.000866	CcSEcCtD
Dolutegravir—Urethral disorder—Capecitabine—breast cancer	0.000365	0.000864	CcSEcCtD
Dolutegravir—Renal impairment—Doxorubicin—breast cancer	0.000365	0.000862	CcSEcCtD
Dolutegravir—Abdominal pain—Thiotepa—breast cancer	0.000362	0.000856	CcSEcCtD
Dolutegravir—Headache—Vinblastine—breast cancer	0.000362	0.000855	CcSEcCtD
Dolutegravir—Insomnia—Irinotecan—breast cancer	0.000358	0.000846	CcSEcCtD
Dolutegravir—Vomiting—Tamoxifen—breast cancer	0.000356	0.000843	CcSEcCtD
Dolutegravir—Vertigo—Paclitaxel—breast cancer	0.000355	0.00084	CcSEcCtD
Dolutegravir—Dizziness—Goserelin—breast cancer	0.000354	0.000837	CcSEcCtD
Dolutegravir—Rash—Tamoxifen—breast cancer	0.000354	0.000836	CcSEcCtD
Dolutegravir—Hypersensitivity—Vinorelbine—breast cancer	0.000353	0.000835	CcSEcCtD
Dolutegravir—Dermatitis—Tamoxifen—breast cancer	0.000353	0.000835	CcSEcCtD
Dolutegravir—Blood creatinine increased—Epirubicin—breast cancer	0.000352	0.000831	CcSEcCtD
Dolutegravir—Headache—Tamoxifen—breast cancer	0.000351	0.00083	CcSEcCtD
Dolutegravir—Vomiting—Melphalan—breast cancer	0.000349	0.000825	CcSEcCtD
Dolutegravir—Insomnia—Gemcitabine—breast cancer	0.000349	0.000824	CcSEcCtD
Dolutegravir—Immune system disorder—Docetaxel—breast cancer	0.000348	0.000822	CcSEcCtD
Dolutegravir—Rash—Melphalan—breast cancer	0.000346	0.000818	CcSEcCtD
Dolutegravir—Dermatitis—Melphalan—breast cancer	0.000346	0.000818	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—GSTM1—breast cancer	0.000345	0.00104	CbGpPWpGaD
Dolutegravir—Asthenia—Vinorelbine—breast cancer	0.000344	0.000813	CcSEcCtD
Dolutegravir—Nausea—Vinblastine—breast cancer	0.000343	0.00081	CcSEcCtD
Dolutegravir—Abdominal pain upper—Epirubicin—breast cancer	0.000343	0.00081	CcSEcCtD
Dolutegravir—Insomnia—Fluorouracil—breast cancer	0.000343	0.00081	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Irinotecan—breast cancer	0.000342	0.000807	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—breast cancer	0.000341	0.00102	CbGpPWpGaD
Dolutegravir—Fatigue—Mitoxantrone—breast cancer	0.000341	0.000806	CcSEcCtD
Dolutegravir—Fatigue—Irinotecan—breast cancer	0.000341	0.000806	CcSEcCtD
Dolutegravir—Vomiting—Goserelin—breast cancer	0.00034	0.000805	CcSEcCtD
Dolutegravir—Pruritus—Vinorelbine—breast cancer	0.000339	0.000802	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—TGFB2—breast cancer	0.000339	0.00102	CbGpPWpGaD
Dolutegravir—Rash—Goserelin—breast cancer	0.000338	0.000798	CcSEcCtD
Dolutegravir—Hypersensitivity—Thiotepa—breast cancer	0.000337	0.000798	CcSEcCtD
Dolutegravir—Dermatitis—Goserelin—breast cancer	0.000337	0.000797	CcSEcCtD
Dolutegravir—Mental disorder—Docetaxel—breast cancer	0.000337	0.000797	CcSEcCtD
Dolutegravir—Immune system disorder—Capecitabine—breast cancer	0.000337	0.000796	CcSEcCtD
Dolutegravir—Headache—Goserelin—breast cancer	0.000335	0.000793	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—breast cancer	0.000334	0.00079	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—MTR—breast cancer	0.000333	0.001	CbGpPWpGaD
Dolutegravir—Nausea—Tamoxifen—breast cancer	0.000333	0.000787	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000333	0.000786	CcSEcCtD
Dolutegravir—Abdominal discomfort—Methotrexate—breast cancer	0.000332	0.000785	CcSEcCtD
Dolutegravir—Fatigue—Gemcitabine—breast cancer	0.000332	0.000785	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Epirubicin—breast cancer	0.000331	0.000782	CcSEcCtD
Dolutegravir—Asthenia—Thiotepa—breast cancer	0.000329	0.000777	CcSEcCtD
Dolutegravir—Diarrhoea—Vinorelbine—breast cancer	0.000328	0.000776	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000327	0.000773	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—HPGDS—breast cancer	0.000327	0.000981	CbGpPWpGaD
Dolutegravir—Mental disorder—Capecitabine—breast cancer	0.000326	0.000772	CcSEcCtD
Dolutegravir—Nausea—Melphalan—breast cancer	0.000326	0.000771	CcSEcCtD
Dolutegravir—Blood creatinine increased—Doxorubicin—breast cancer	0.000325	0.000769	CcSEcCtD
Dolutegravir—Neutropenia—Methotrexate—breast cancer	0.000324	0.000766	CcSEcCtD
Dolutegravir—Pruritus—Thiotepa—breast cancer	0.000324	0.000766	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Irinotecan—breast cancer	0.000323	0.000765	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Mitoxantrone—breast cancer	0.000323	0.000765	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—SQSTM1—breast cancer	0.00032	0.000961	CbGpPWpGaD
Dolutegravir—Flatulence—Capecitabine—breast cancer	0.00032	0.000756	CcSEcCtD
Dolutegravir—Nausea—Goserelin—breast cancer	0.000318	0.000752	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTT1—breast cancer	0.000317	0.000951	CbGpPWpGaD
Dolutegravir—Dizziness—Vinorelbine—breast cancer	0.000317	0.00075	CcSEcCtD
Dolutegravir—Abdominal pain upper—Doxorubicin—breast cancer	0.000317	0.00075	CcSEcCtD
Dolutegravir—Nervous system disorder—Paclitaxel—breast cancer	0.000316	0.000748	CcSEcCtD
Dolutegravir—Diarrhoea—Thiotepa—breast cancer	0.000313	0.000741	CcSEcCtD
Dolutegravir—Skin disorder—Paclitaxel—breast cancer	0.000313	0.000741	CcSEcCtD
Dolutegravir—Abdominal pain—Mitoxantrone—breast cancer	0.000313	0.000739	CcSEcCtD
Dolutegravir—Abdominal pain—Irinotecan—breast cancer	0.000313	0.000739	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—SLC5A5—breast cancer	0.000311	0.000933	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—breast cancer	0.00031	0.000929	CbGpPWpGaD
Dolutegravir—Alanine aminotransferase increased—Doxorubicin—breast cancer	0.000306	0.000724	CcSEcCtD
Dolutegravir—Vomiting—Vinorelbine—breast cancer	0.000305	0.000721	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—breast cancer	0.000304	0.000913	CbGpPWpGaD
Dolutegravir—Renal failure—Methotrexate—breast cancer	0.000304	0.000718	CcSEcCtD
Dolutegravir—Neutropenia—Epirubicin—breast cancer	0.000303	0.000717	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—breast cancer	0.000303	0.000909	CbGpPWpGaD
Dolutegravir—Dizziness—Thiotepa—breast cancer	0.000303	0.000716	CcSEcCtD
Dolutegravir—Rash—Vinorelbine—breast cancer	0.000302	0.000715	CcSEcCtD
Dolutegravir—Dermatitis—Vinorelbine—breast cancer	0.000302	0.000714	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—NQO1—breast cancer	0.000301	0.000901	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—SLC2A1—breast cancer	0.000301	0.000901	CbGpPWpGaD
Dolutegravir—Headache—Vinorelbine—breast cancer	0.0003	0.00071	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP17A1—breast cancer	0.0003	0.0009	CbGpPWpGaD
Dolutegravir—UGT1A1—Biological oxidations—PTGS1—breast cancer	0.000297	0.000891	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP17A1—breast cancer	0.000296	0.000888	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—breast cancer	0.000295	0.000884	CbGpPWpGaD
Dolutegravir—Hyperglycaemia—Epirubicin—breast cancer	0.000293	0.000692	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Methotrexate—breast cancer	0.000292	0.000691	CcSEcCtD
Dolutegravir—Insomnia—Paclitaxel—breast cancer	0.000292	0.00069	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP2D6—breast cancer	0.000291	0.000874	CbGpPWpGaD
Dolutegravir—Vertigo—Capecitabine—breast cancer	0.000291	0.000689	CcSEcCtD
Dolutegravir—Hypersensitivity—Mitoxantrone—breast cancer	0.000291	0.000689	CcSEcCtD
Dolutegravir—Hypersensitivity—Irinotecan—breast cancer	0.000291	0.000689	CcSEcCtD
Dolutegravir—Vomiting—Thiotepa—breast cancer	0.000291	0.000688	CcSEcCtD
Dolutegravir—Rash—Thiotepa—breast cancer	0.000289	0.000683	CcSEcCtD
Dolutegravir—Dermatitis—Thiotepa—breast cancer	0.000289	0.000682	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP2D6—breast cancer	0.000287	0.000862	CbGpPWpGaD
Dolutegravir—Headache—Thiotepa—breast cancer	0.000287	0.000678	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—NCOA2—breast cancer	0.000286	0.000858	CbGpPWpGaD
Dolutegravir—Nausea—Vinorelbine—breast cancer	0.000285	0.000673	CcSEcCtD
Dolutegravir—Renal failure—Epirubicin—breast cancer	0.000284	0.000672	CcSEcCtD
Dolutegravir—Asthenia—Mitoxantrone—breast cancer	0.000284	0.000671	CcSEcCtD
Dolutegravir—Asthenia—Irinotecan—breast cancer	0.000284	0.000671	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000283	0.00067	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—HSP90AA1—breast cancer	0.000283	0.000847	CbGpPWpGaD
Dolutegravir—Neutropenia—Doxorubicin—breast cancer	0.000281	0.000663	CcSEcCtD
Dolutegravir—Hypersensitivity—Fluorouracil—breast cancer	0.000279	0.00066	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—EGR1—breast cancer	0.000279	0.000837	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000279	0.000658	CcSEcCtD
Dolutegravir—Fatigue—Paclitaxel—breast cancer	0.000278	0.000657	CcSEcCtD
Dolutegravir—Hepatitis—Methotrexate—breast cancer	0.000277	0.000656	CcSEcCtD
Dolutegravir—Asthenia—Gemcitabine—breast cancer	0.000276	0.000654	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000274	0.000648	CcSEcCtD
Dolutegravir—Urinary tract disorder—Methotrexate—breast cancer	0.000274	0.000648	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Epirubicin—breast cancer	0.000273	0.000647	CcSEcCtD
Dolutegravir—Pruritus—Gemcitabine—breast cancer	0.000273	0.000644	CcSEcCtD
Dolutegravir—Nausea—Thiotepa—breast cancer	0.000272	0.000643	CcSEcCtD
Dolutegravir—Urethral disorder—Methotrexate—breast cancer	0.000272	0.000643	CcSEcCtD
Dolutegravir—Hyperglycaemia—Doxorubicin—breast cancer	0.000271	0.00064	CcSEcCtD
Dolutegravir—Diarrhoea—Irinotecan—breast cancer	0.000271	0.00064	CcSEcCtD
Dolutegravir—Diarrhoea—Mitoxantrone—breast cancer	0.000271	0.00064	CcSEcCtD
Dolutegravir—Nervous system disorder—Docetaxel—breast cancer	0.000268	0.000634	CcSEcCtD
Dolutegravir—Pruritus—Fluorouracil—breast cancer	0.000268	0.000634	CcSEcCtD
Dolutegravir—Skin disorder—Docetaxel—breast cancer	0.000266	0.000628	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—breast cancer	0.000265	0.000793	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Paclitaxel—breast cancer	0.000264	0.000624	CcSEcCtD
Dolutegravir—Diarrhoea—Gemcitabine—breast cancer	0.000264	0.000623	CcSEcCtD
Dolutegravir—Renal failure—Doxorubicin—breast cancer	0.000263	0.000622	CcSEcCtD
Dolutegravir—Dizziness—Irinotecan—breast cancer	0.000262	0.000618	CcSEcCtD
Dolutegravir—Nervous system disorder—Capecitabine—breast cancer	0.00026	0.000614	CcSEcCtD
Dolutegravir—Hepatitis—Epirubicin—breast cancer	0.00026	0.000614	CcSEcCtD
Dolutegravir—Diarrhoea—Fluorouracil—breast cancer	0.000259	0.000613	CcSEcCtD
Dolutegravir—Skin disorder—Capecitabine—breast cancer	0.000257	0.000608	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP3A4—breast cancer	0.000257	0.000771	CbGpPWpGaD
Dolutegravir—Urinary tract disorder—Epirubicin—breast cancer	0.000256	0.000606	CcSEcCtD
Dolutegravir—Abdominal pain—Paclitaxel—breast cancer	0.000255	0.000603	CcSEcCtD
Dolutegravir—Urethral disorder—Epirubicin—breast cancer	0.000254	0.000602	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP3A4—breast cancer	0.000254	0.00076	CbGpPWpGaD
Dolutegravir—Hepatobiliary disease—Doxorubicin—breast cancer	0.000253	0.000598	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP1B1—breast cancer	0.000253	0.000758	CbGpPWpGaD
Dolutegravir—Vomiting—Mitoxantrone—breast cancer	0.000252	0.000595	CcSEcCtD
Dolutegravir—Vomiting—Irinotecan—breast cancer	0.000252	0.000595	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—TGFBR2—breast cancer	0.000251	0.000752	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTP1—breast cancer	0.000251	0.000752	CbGpPWpGaD
Dolutegravir—Immune system disorder—Methotrexate—breast cancer	0.000251	0.000592	CcSEcCtD
Dolutegravir—Dizziness—Fluorouracil—breast cancer	0.000251	0.000592	CcSEcCtD
Dolutegravir—Rash—Irinotecan—breast cancer	0.000249	0.00059	CcSEcCtD
Dolutegravir—Rash—Mitoxantrone—breast cancer	0.000249	0.00059	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP1B1—breast cancer	0.000249	0.000747	CbGpPWpGaD
Dolutegravir—Dermatitis—Irinotecan—breast cancer	0.000249	0.000589	CcSEcCtD
Dolutegravir—Dermatitis—Mitoxantrone—breast cancer	0.000249	0.000589	CcSEcCtD
Dolutegravir—Headache—Mitoxantrone—breast cancer	0.000248	0.000586	CcSEcCtD
Dolutegravir—Headache—Irinotecan—breast cancer	0.000248	0.000586	CcSEcCtD
Dolutegravir—Insomnia—Docetaxel—breast cancer	0.000247	0.000585	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—HMOX1—breast cancer	0.000247	0.000741	CbGpPWpGaD
Dolutegravir—Vomiting—Gemcitabine—breast cancer	0.000245	0.000579	CcSEcCtD
Dolutegravir—Mental disorder—Methotrexate—breast cancer	0.000243	0.000575	CcSEcCtD
Dolutegravir—Rash—Gemcitabine—breast cancer	0.000243	0.000574	CcSEcCtD
Dolutegravir—Dermatitis—Gemcitabine—breast cancer	0.000243	0.000574	CcSEcCtD
Dolutegravir—Headache—Gemcitabine—breast cancer	0.000241	0.000571	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—NCOA1—breast cancer	0.000241	0.000723	CbGpPWpGaD
Dolutegravir—Vomiting—Fluorouracil—breast cancer	0.000241	0.000569	CcSEcCtD
Dolutegravir—Hepatitis—Doxorubicin—breast cancer	0.00024	0.000568	CcSEcCtD
Dolutegravir—Insomnia—Capecitabine—breast cancer	0.000239	0.000566	CcSEcCtD
Dolutegravir—Rash—Fluorouracil—breast cancer	0.000239	0.000565	CcSEcCtD
Dolutegravir—Dermatitis—Fluorouracil—breast cancer	0.000239	0.000564	CcSEcCtD
Dolutegravir—Hypersensitivity—Paclitaxel—breast cancer	0.000238	0.000562	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP19A1—breast cancer	0.000238	0.000712	CbGpPWpGaD
Dolutegravir—Headache—Fluorouracil—breast cancer	0.000237	0.000561	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—breast cancer	0.000237	0.000561	CcSEcCtD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—breast cancer	0.000237	0.000709	CbGpPWpGaD
Dolutegravir—Gastrointestinal disorder—Docetaxel—breast cancer	0.000236	0.000558	CcSEcCtD
Dolutegravir—Fatigue—Docetaxel—breast cancer	0.000236	0.000557	CcSEcCtD
Dolutegravir—Urethral disorder—Doxorubicin—breast cancer	0.000235	0.000557	CcSEcCtD
Dolutegravir—Nausea—Irinotecan—breast cancer	0.000235	0.000555	CcSEcCtD
Dolutegravir—Nausea—Mitoxantrone—breast cancer	0.000235	0.000555	CcSEcCtD
Dolutegravir—Immune system disorder—Epirubicin—breast cancer	0.000234	0.000554	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP19A1—breast cancer	0.000234	0.000703	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—breast cancer	0.000232	0.000695	CbGpPWpGaD
Dolutegravir—Asthenia—Paclitaxel—breast cancer	0.000231	0.000547	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—HGF—breast cancer	0.00023	0.000691	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—GSTM1—breast cancer	0.00023	0.000691	CbGpPWpGaD
Dolutegravir—Nausea—Gemcitabine—breast cancer	0.000229	0.000541	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Capecitabine—breast cancer	0.000229	0.00054	CcSEcCtD
Dolutegravir—Fatigue—Capecitabine—breast cancer	0.000228	0.00054	CcSEcCtD
Dolutegravir—Pruritus—Paclitaxel—breast cancer	0.000228	0.00054	CcSEcCtD
Dolutegravir—Mental disorder—Epirubicin—breast cancer	0.000227	0.000538	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—NRG1—breast cancer	0.000226	0.000678	CbGpPWpGaD
Dolutegravir—Nausea—Fluorouracil—breast cancer	0.000225	0.000532	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Docetaxel—breast cancer	0.000224	0.000529	CcSEcCtD
Dolutegravir—Flatulence—Epirubicin—breast cancer	0.000223	0.000526	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—COMT—breast cancer	0.000221	0.000662	CbGpPWpGaD
Dolutegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—breast cancer	0.000221	0.000662	CbGpPWpGaD
Dolutegravir—Diarrhoea—Paclitaxel—breast cancer	0.000221	0.000522	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTP1—breast cancer	0.00022	0.000659	CbGpPWpGaD
Dolutegravir—UGT1A1—Metapathway biotransformation—COMT—breast cancer	0.000218	0.000653	CbGpPWpGaD
Dolutegravir—Immune system disorder—Doxorubicin—breast cancer	0.000217	0.000513	CcSEcCtD
Dolutegravir—Vertigo—Methotrexate—breast cancer	0.000217	0.000513	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTP1—breast cancer	0.000217	0.00065	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Capecitabine—breast cancer	0.000216	0.000512	CcSEcCtD
Dolutegravir—Abdominal pain—Docetaxel—breast cancer	0.000216	0.000511	CcSEcCtD
Dolutegravir—Dizziness—Paclitaxel—breast cancer	0.000213	0.000504	CcSEcCtD
Dolutegravir—Mental disorder—Doxorubicin—breast cancer	0.00021	0.000497	CcSEcCtD
Dolutegravir—Abdominal pain—Capecitabine—breast cancer	0.000209	0.000495	CcSEcCtD
Dolutegravir—Flatulence—Doxorubicin—breast cancer	0.000206	0.000487	CcSEcCtD
Dolutegravir—Vomiting—Paclitaxel—breast cancer	0.000205	0.000485	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000204	0.000483	CcSEcCtD
Dolutegravir—Rash—Paclitaxel—breast cancer	0.000203	0.000481	CcSEcCtD
Dolutegravir—Dermatitis—Paclitaxel—breast cancer	0.000203	0.00048	CcSEcCtD
Dolutegravir—Vertigo—Epirubicin—breast cancer	0.000203	0.00048	CcSEcCtD
Dolutegravir—Headache—Paclitaxel—breast cancer	0.000202	0.000478	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—GSTM1—breast cancer	0.000202	0.000606	CbGpPWpGaD
Dolutegravir—Hypersensitivity—Docetaxel—breast cancer	0.000201	0.000476	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—GSTM1—breast cancer	0.000199	0.000597	CbGpPWpGaD
Dolutegravir—Asthenia—Docetaxel—breast cancer	0.000196	0.000464	CcSEcCtD
Dolutegravir—Hypersensitivity—Capecitabine—breast cancer	0.000195	0.000461	CcSEcCtD
Dolutegravir—Pruritus—Docetaxel—breast cancer	0.000193	0.000457	CcSEcCtD
Dolutegravir—Nervous system disorder—Methotrexate—breast cancer	0.000193	0.000457	CcSEcCtD
Dolutegravir—Nausea—Paclitaxel—breast cancer	0.000192	0.000453	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—CYP1A1—breast cancer	0.000192	0.000574	CbGpPWpGaD
Dolutegravir—Skin disorder—Methotrexate—breast cancer	0.000191	0.000453	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000191	0.000452	CcSEcCtD
Dolutegravir—Asthenia—Capecitabine—breast cancer	0.00019	0.000449	CcSEcCtD
Dolutegravir—UGT1A1—Metapathway biotransformation—CYP1A1—breast cancer	0.000189	0.000566	CbGpPWpGaD
Dolutegravir—Vertigo—Doxorubicin—breast cancer	0.000188	0.000444	CcSEcCtD
Dolutegravir—Pruritus—Capecitabine—breast cancer	0.000187	0.000443	CcSEcCtD
Dolutegravir—Diarrhoea—Docetaxel—breast cancer	0.000187	0.000442	CcSEcCtD
Dolutegravir—Diarrhoea—Capecitabine—breast cancer	0.000181	0.000428	CcSEcCtD
Dolutegravir—Nervous system disorder—Epirubicin—breast cancer	0.000181	0.000428	CcSEcCtD
Dolutegravir—Dizziness—Docetaxel—breast cancer	0.000181	0.000427	CcSEcCtD
Dolutegravir—Skin disorder—Epirubicin—breast cancer	0.000179	0.000423	CcSEcCtD
Dolutegravir—Insomnia—Methotrexate—breast cancer	0.000178	0.000421	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000177	0.000418	CcSEcCtD
Dolutegravir—Dizziness—Capecitabine—breast cancer	0.000175	0.000414	CcSEcCtD
Dolutegravir—Vomiting—Docetaxel—breast cancer	0.000174	0.000411	CcSEcCtD
Dolutegravir—Rash—Docetaxel—breast cancer	0.000172	0.000408	CcSEcCtD
Dolutegravir—Dermatitis—Docetaxel—breast cancer	0.000172	0.000407	CcSEcCtD
Dolutegravir—Headache—Docetaxel—breast cancer	0.000171	0.000405	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Methotrexate—breast cancer	0.00017	0.000402	CcSEcCtD
Dolutegravir—Fatigue—Methotrexate—breast cancer	0.00017	0.000402	CcSEcCtD
Dolutegravir—Vomiting—Capecitabine—breast cancer	0.000168	0.000398	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—breast cancer	0.000167	0.000396	CcSEcCtD
Dolutegravir—Rash—Capecitabine—breast cancer	0.000167	0.000395	CcSEcCtD
Dolutegravir—Insomnia—Epirubicin—breast cancer	0.000167	0.000394	CcSEcCtD
Dolutegravir—Dermatitis—Capecitabine—breast cancer	0.000167	0.000394	CcSEcCtD
Dolutegravir—Headache—Capecitabine—breast cancer	0.000166	0.000392	CcSEcCtD
Dolutegravir—Skin disorder—Doxorubicin—breast cancer	0.000166	0.000392	CcSEcCtD
Dolutegravir—Nausea—Docetaxel—breast cancer	0.000162	0.000384	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Methotrexate—breast cancer	0.000161	0.000381	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Epirubicin—breast cancer	0.000159	0.000376	CcSEcCtD
Dolutegravir—Fatigue—Epirubicin—breast cancer	0.000159	0.000376	CcSEcCtD
Dolutegravir—Nausea—Capecitabine—breast cancer	0.000157	0.000372	CcSEcCtD
Dolutegravir—Abdominal pain—Methotrexate—breast cancer	0.000156	0.000368	CcSEcCtD
Dolutegravir—Insomnia—Doxorubicin—breast cancer	0.000154	0.000365	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—SYNJ2—breast cancer	0.000154	0.000462	CbGpPWpGaD
Dolutegravir—Gastrointestinal pain—Epirubicin—breast cancer	0.000151	0.000357	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—breast cancer	0.000147	0.000348	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—breast cancer	0.000147	0.000348	CcSEcCtD
Dolutegravir—Abdominal pain—Epirubicin—breast cancer	0.000146	0.000345	CcSEcCtD
Dolutegravir—Hypersensitivity—Methotrexate—breast cancer	0.000145	0.000343	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—NDUFS3—breast cancer	0.000143	0.00043	CbGpPWpGaD
Dolutegravir—Asthenia—Methotrexate—breast cancer	0.000141	0.000334	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Doxorubicin—breast cancer	0.00014	0.00033	CcSEcCtD
Dolutegravir—Pruritus—Methotrexate—breast cancer	0.000139	0.00033	CcSEcCtD
Dolutegravir—Hypersensitivity—Epirubicin—breast cancer	0.000136	0.000321	CcSEcCtD
Dolutegravir—Abdominal pain—Doxorubicin—breast cancer	0.000135	0.000319	CcSEcCtD
Dolutegravir—Diarrhoea—Methotrexate—breast cancer	0.000135	0.000319	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CHST9—breast cancer	0.000135	0.000404	CbGpPWpGaD
Dolutegravir—Asthenia—Epirubicin—breast cancer	0.000132	0.000313	CcSEcCtD
Dolutegravir—Pruritus—Epirubicin—breast cancer	0.00013	0.000308	CcSEcCtD
Dolutegravir—Dizziness—Methotrexate—breast cancer	0.00013	0.000308	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—COX11—breast cancer	0.000128	0.000383	CbGpPWpGaD
Dolutegravir—Diarrhoea—Epirubicin—breast cancer	0.000126	0.000298	CcSEcCtD
Dolutegravir—Hypersensitivity—Doxorubicin—breast cancer	0.000126	0.000297	CcSEcCtD
Dolutegravir—Vomiting—Methotrexate—breast cancer	0.000125	0.000296	CcSEcCtD
Dolutegravir—Rash—Methotrexate—breast cancer	0.000124	0.000294	CcSEcCtD
Dolutegravir—Dermatitis—Methotrexate—breast cancer	0.000124	0.000293	CcSEcCtD
Dolutegravir—Headache—Methotrexate—breast cancer	0.000123	0.000292	CcSEcCtD
Dolutegravir—Asthenia—Doxorubicin—breast cancer	0.000122	0.000289	CcSEcCtD
Dolutegravir—Dizziness—Epirubicin—breast cancer	0.000122	0.000288	CcSEcCtD
Dolutegravir—Pruritus—Doxorubicin—breast cancer	0.000121	0.000285	CcSEcCtD
Dolutegravir—Vomiting—Epirubicin—breast cancer	0.000117	0.000277	CcSEcCtD
Dolutegravir—Nausea—Methotrexate—breast cancer	0.000117	0.000277	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—CDA—breast cancer	0.000117	0.00035	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SHMT1—breast cancer	0.000117	0.00035	CbGpPWpGaD
Dolutegravir—Diarrhoea—Doxorubicin—breast cancer	0.000117	0.000276	CcSEcCtD
Dolutegravir—Rash—Epirubicin—breast cancer	0.000116	0.000275	CcSEcCtD
Dolutegravir—Dermatitis—Epirubicin—breast cancer	0.000116	0.000275	CcSEcCtD
Dolutegravir—Headache—Epirubicin—breast cancer	0.000116	0.000273	CcSEcCtD
Dolutegravir—Dizziness—Doxorubicin—breast cancer	0.000113	0.000267	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—SLC2A5—breast cancer	0.000112	0.000337	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLCO1B1—breast cancer	0.000112	0.000337	CbGpPWpGaD
Dolutegravir—Nausea—Epirubicin—breast cancer	0.00011	0.000259	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—APRT—breast cancer	0.000109	0.000326	CbGpPWpGaD
Dolutegravir—Vomiting—Doxorubicin—breast cancer	0.000109	0.000256	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—breast cancer	0.000108	0.000254	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—breast cancer	0.000108	0.000254	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—breast cancer	0.000107	0.000253	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—ESRRA—breast cancer	0.000102	0.000306	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ANGPTL4—breast cancer	0.000102	0.000306	CbGpPWpGaD
Dolutegravir—Nausea—Doxorubicin—breast cancer	0.000101	0.00024	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—GPI—breast cancer	9.68e-05	0.00029	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HADHB—breast cancer	9.68e-05	0.00029	CbGpPWpGaD
Dolutegravir—UGT1A1—NRF2 pathway—TGFB1—breast cancer	9.39e-05	0.000282	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALDH7A1—breast cancer	9.23e-05	0.000277	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALDH1A1—breast cancer	9.23e-05	0.000277	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—FHL2—breast cancer	8.85e-05	0.000265	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NME1—breast cancer	8.85e-05	0.000265	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—UMPS—breast cancer	8.85e-05	0.000265	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ADSL—breast cancer	8.85e-05	0.000265	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PHGDH—breast cancer	8.85e-05	0.000265	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—BRIP1—breast cancer	8.68e-05	0.00026	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HPSE—breast cancer	8.68e-05	0.00026	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—LDHB—breast cancer	8.68e-05	0.00026	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCC1—breast cancer	8.23e-05	0.000247	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA3—breast cancer	8.23e-05	0.000247	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HMMR—breast cancer	8.23e-05	0.000247	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PPARGC1B—breast cancer	7.97e-05	0.000239	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA4—breast cancer	7.52e-05	0.000226	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CA9—breast cancer	7.52e-05	0.000226	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA2—breast cancer	7.33e-05	0.00022	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GPX2—breast cancer	7.33e-05	0.00022	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GPX4—breast cancer	7.24e-05	0.000217	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SULT1A1—breast cancer	7.24e-05	0.000217	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—IDH1—breast cancer	7.07e-05	0.000212	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTA1—breast cancer	7.07e-05	0.000212	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NAT2—breast cancer	7e-05	0.00021	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MED12—breast cancer	6.13e-05	0.000184	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—DPYD—breast cancer	6.13e-05	0.000184	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALDOA—breast cancer	6.04e-05	0.000181	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NCOA3—breast cancer	5.86e-05	0.000176	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC2A2—breast cancer	5.82e-05	0.000175	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCG2—breast cancer	5.7e-05	0.000171	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MTR—breast cancer	5.7e-05	0.000171	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CPT1A—breast cancer	5.7e-05	0.000171	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HPGDS—breast cancer	5.59e-05	0.000168	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HBA1—breast cancer	5.56e-05	0.000167	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTT1—breast cancer	5.42e-05	0.000163	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ACHE—breast cancer	5.42e-05	0.000163	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP17A1—breast cancer	5.13e-05	0.000154	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ENO1—breast cancer	5.08e-05	0.000152	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS1—breast cancer	5.08e-05	0.000152	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP2D6—breast cancer	4.98e-05	0.000149	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NCOA2—breast cancer	4.89e-05	0.000147	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—FASN—breast cancer	4.75e-05	0.000142	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—BCHE—breast cancer	4.73e-05	0.000142	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC5A5—breast cancer	4.67e-05	0.00014	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NQO1—breast cancer	4.51e-05	0.000135	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—SLC2A1—breast cancer	4.51e-05	0.000135	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP3A4—breast cancer	4.4e-05	0.000132	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP1B1—breast cancer	4.32e-05	0.00013	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HSP90AA1—breast cancer	4.24e-05	0.000127	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NCOA1—breast cancer	4.12e-05	0.000124	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—STK11—breast cancer	4.06e-05	0.000122	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP19A1—breast cancer	4.06e-05	0.000122	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—COMT—breast cancer	3.78e-05	0.000113	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTP1—breast cancer	3.76e-05	0.000113	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—HMOX1—breast cancer	3.71e-05	0.000111	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ITPR1—breast cancer	3.7e-05	0.000111	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ABCB1—breast cancer	3.56e-05	0.000107	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—TYMS—breast cancer	3.5e-05	0.000105	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GSTM1—breast cancer	3.46e-05	0.000104	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PLA2G4A—breast cancer	3.46e-05	0.000104	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NCOR1—breast cancer	3.46e-05	0.000104	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—GPX1—breast cancer	3.31e-05	9.92e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CYP1A1—breast cancer	3.28e-05	9.82e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ERCC2—breast cancer	3.25e-05	9.74e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—MTHFR—breast cancer	3.05e-05	9.16e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—CAV1—breast cancer	2.82e-05	8.45e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CG—breast cancer	2.57e-05	7.69e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CD—breast cancer	2.26e-05	6.76e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—ALB—breast cancer	2.23e-05	6.68e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—NOS3—breast cancer	2.13e-05	6.39e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CB—breast cancer	1.97e-05	5.89e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTGS2—breast cancer	1.95e-05	5.84e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PTEN—breast cancer	1.7e-05	5.09e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—PIK3CA—breast cancer	1.2e-05	3.59e-05	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—AKT1—breast cancer	9.79e-06	2.94e-05	CbGpPWpGaD
